ERG expression and prostatic adenocarcinoma

Virchows Archiv

Volumn 462, Issue 6, 2013, Pages 639-644

  Verdu, Montse ^a,b   Trias, Isabel ^a,b,c,f   Roman, Ruth ^a   Rodon, Natalia ^a   Garcia Pelaez, Beatriz ^a   Calvo, Miquel ^d   Dominguez, Arturo ^e   Banus, Josep M ^e   Puig, Xavier ^a,b,f  

^a BIOPAT   (Spain)

^b Histopat Laboratoris   (Spain)

^c HOSPITAL PLATÓ   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e Institut Català d'Urologia i Nefrologia   (Spain)

^f Hospital de Niños de Barcelona   (Spain)

Author keywords

Clone EPR3864; ERG rearrangement; Immunohistochemistry; Prostate cancer; TMPRSS2:ERG

Indexed keywords

TRANSCRIPTION FACTOR ERG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER TISSUE; CAUCASIAN; COLON CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; GENE EXPRESSION; GENE REARRANGEMENT; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SENSITIVITY AND SPECIFICITY; SPAIN; STAINING; TISSUE MICROARRAY; TUMOR INVASION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SPAIN; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS;

EID: 84878925248     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1415-3     Document Type: Article

References (26)

1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781. doi: 10.1016j/ejca.2009.12.014
2. Perner S, Demichelis F, Beroukhim R et al (2006) TMPRSS2:ERG fusion-associated deletions provide insight into heterogeneity of prostate cancer. Cancer Res 66(17):8337-8341. doi: 10.1158/0008-5472.CAN-06-1468
3. Wang J, Cai Y, Ren C, Ittmann M (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66:8347-8351. doi: 10.1158/0008-5472.CAN-06-1966
4. Clark JP, Cooper CS (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6:429-439. doi: 10.1038/nrurol.2009.127
5. Park K, Tomlins SA, Mudaliar KM et al (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12(7):590-598. doi: 10.1593/neo.10726
6. Falzarano SM, Zhou M, Carver P et al (2011) ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch 459(4):441-447. doi: 10.1007/s00428-011-1128-4
7. Chaux A, Albadine R, Toubaji A et al (2011) Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 35:1014-1020. doi: 10.1097/PAS. 0b013e31821e8761
8. R Core Team (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/.
9. Verzani J (2004) Using R for introductory statistics. Chapman & Hall/CRC, Boca Raton
10. Mosquera JM, Mehra R, Regan MM et al (2009) Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the united states. Clin Cancer Res 15(14):4706-4711. doi: 10.1158/1078-0432.CCR-08-2927
11. Magi-Galluzzi C, Tsusuki T, Elson P et al (2011) TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71:489-497. doi: 10.1002/pros.21265
12. Miyagi Y, Sasaki T, Fujinami K et al (2010) ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol 23:1492-1498. doi: 10.1038/modpathol.2010.149
13. Minner S, Enodien M, Sirma H et al (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Can Res 17(18):5878-5888. doi: 10.1158/1078-0432.CCR-11-1251
14. Mosquera JM, Perner S, Genega EM et al (2008) Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 14(11):3380-3385. doi: 10.1158/1078-0432.CCR-07-5194
15. Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP (2012) Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases. Arch Pathol Lab Med 136:935-946. doi: 10.5858/arpa.2011-0424-OA
16. Han B, Mehra R, Lonigro R et al (2009) Fluorescent in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 22(8):1083-1093. doi: 10.1038/modpathol.2009.69
17. Falzarano SM, Navas M, Simmerman K et al (2010) ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol 23:1499-1506. doi: 10.1038/modpathol.2010.150
18. Van Leenders GJ, Boormans JL, Vissers CJ et al (2011) Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 24(8):1128-1138. doi: 10.1038/modpathol.2011. 65
19. Demichelis F, Fall K, Perner S et al (2007) TMPRSS2-ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31):4596-4599. doi: 10.1038/sj.onc.1210237
20. Furusato B, Tan S-H, Young D et al (2010) ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 13(3):228-237. doi: 10.1038/pcan.2010.23
21. He H, Magi-Galluzzi C, Li J et al (2011) The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". Am J Surg Pathol 35(4):608-614. doi: 10.1097/PAS.0b013e31820bcd2d
22. Yaskiv O, Zhang X, Simmerman K et al (2011) The utility of ERG/p63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol 35(7):1062-1068. doi: 10.1097/PAS. 0b013e318215cc03
23. Jiang Z, Li C, Fischer A, Dresser K, Woda BA (2005) Using an AMACR (P504S)/34bE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol 123:231-236
24. Perner S, Mosquera JM, Demichelis F et al (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31:882-888
25. Scheble VJ, Braun M, Beroukhim R et al (2010) ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 23:1061-1067. doi: 10.1038/modpathol.2010.87
26. Miettinen M, Wang Z-F, Anders P et al (2011) ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 35:432-441. doi: 10.1097/PAS.0b013e318206b67b